• If you are wondering whether Abbott Laboratories at around US$105 per share looks like an opportunity or a value trap, the starting point is understanding what the current price actually reflects.
• The stock has seen a 2.4% decline over the past week, a 6.9% decline over the last month, and a 15.1% decline year to date, with a 15.0% decline over the past year and a 14.1% gain over three years.
• These moves are set against a backdrop of ongoing attention on large healthcare names, with investors weighing long term demand for medical equipment and diagnostics alongside broader market sentiment. Coverage of the sector has also focused on how established players balance growth initiatives and capital allocation, which can influence how investors think about risk and reward in the share price.
• On Simply Wall St’s valuation checks, Abbott Laboratories currently scores 5 out of 6. This raises useful questions about where the market may be conservative and where expectations already look full. This article will walk through the key valuation methods before ending with a way to put those numbers into a clearer investing story.

Approach 1: Abbott Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes projected future cash flows and discounts them back to today so you can compare that value with the current share price.

For Abbott Laboratories, Simply Wall St uses a 2 Stage Free Cash Flow to Equity model based on cash flow projections. The latest twelve month free cash flow is about $7.26b. Analysts contribute the nearer term forecasts, and for Abbott this extends out to a projected free cash flow of $11.46b in 2028, with further years extrapolated by Simply Wall St to build a 10 year path of cash flows.

When those future cash flows are discounted back to today, the DCF model arrives at an estimated intrinsic value of about $164.42 per share. Against a current share price around $105, this implies the stock trades at roughly a 35.9% discount to that estimate. Within this framework, the shares are assessed as undervalued.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Abbott Laboratories is undervalued by 35.9%. Track this in your watchlist or portfolio, or discover 52 more high quality undervalued stocks.

Approach 2: Abbott Laboratories Price vs Earnings

For a profitable company, the P/E ratio is a useful shorthand for what the market is paying for each dollar of earnings, which is why it is often the go-to multiple for established healthcare names like Abbott Laboratories.

What counts as a “normal” P/E depends on what investors expect for future growth and how much risk they see in those earnings. Higher expected growth or lower perceived risk can support a higher P/E, while lower growth or higher risk typically align with a lower multiple.

Abbott currently trades on a P/E of 28.26x, compared with the Medical Equipment industry average of 26.87x and a peer group average of 39.66x. Simply Wall St also calculates a proprietary “Fair Ratio” of 40.44x for Abbott, which reflects factors like its earnings growth profile, profit margins, industry, market cap and company specific risks.

This Fair Ratio aims to be more tailored than a simple comparison against peers or the industry, because it adjusts for Abbott’s own characteristics rather than assuming a one-size-fits-all benchmark. Set against the current P/E of 28.26x, the Fair Ratio of 40.44x suggests the shares trade below what that model would indicate.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Abbott Laboratories Narrative

Earlier it was mentioned that there is an even better way to understand valuation, so this is where Narratives come in, giving you a clear story behind the numbers such as your fair value, and your assumptions for future revenue, earnings and margins.

A Narrative on Simply Wall St is your own explanation of what Abbott Laboratories is, how it competes across medical devices, diagnostics, nutrition and pharmaceuticals, and how that story connects to a financial forecast that leads to a fair value per share.

On the Community page, where millions of investors share their work, Narratives turn that story into numbers so you can compare each Narrative fair value against the current price and quickly see whether a particular view treats Abbott as closer to an opportunity or closer to fully priced.

Because Narratives update automatically when new information such as earnings results, clinical news or analyst targets are added to the platform, your thesis does not sit still while the company and its market move.

For Abbott, one Narrative might lean closer to the higher analyst price target of US$159, built on confidence in long term demand and product pipelines. Another might sit nearer the lower target of US$122, reflecting more weight on risks like pricing pressure, regulation and competition. The gap between those two views shows how different but clearly defined stories can point to very different fair values for the same stock.

Do you think there's more to the story for Abbott Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.